Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Work In Process of $33.0 million for Q1 2026, up 44.02% year-over-year from $22.9 million in Q1 2025, and up 22.22% quarter-over-quarter from $27.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Work In Process for 10 consecutive years, with $33.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Work In Process rose 44.02% year-over-year to $33.0 million; the TTM figure through Mar 2026 stood at $33.0 million (up 44.02% YoY), while the FY2025 annual figure was $27.0 million, up 22.73% from the prior year.
- Work In Process climbed to $33.0 million in Q1 2026 per RARE's latest filing, from $27.0 million in the prior quarter.
- Across five years, Work In Process topped out at $33.0 million in Q1 2026 and bottomed at $12.0 million in Q1 2022.
- Historically, Work In Process has averaged $20.9 million across 5 years, with a median of $19.8 million in 2025.
- Annual changes were most pronounced in 2022 — Work In Process soared 76.75% — and 2025, when it dropped 21.77%.
- Ultragenyx Pharmaceutical's Work In Process stood at $17.5 million in 2022, then climbed by 7.85% to $18.9 million in 2023, then increased by 16.66% to $22.0 million in 2024, then climbed by 22.73% to $27.0 million in 2025, then climbed by 22.22% to $33.0 million in 2026.
- Business Quant data shows RARE's Work In Process at $33.0 million in Q1 2026, $27.0 million in Q4 2025, and $29.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.00 Mn |
| Mar 31, 2026 | 33.00 Mn |
| Dec 31, 2025 | 27.00 Mn |
| Sep 30, 2025 | 29.19 Mn |
| Jun 30, 2025 | 19.76 Mn |
| Mar 31, 2025 | 22.91 Mn |
| Dec 31, 2024 | 22.00 Mn |
| Sep 30, 2024 | 20.28 Mn |
| Jun 30, 2024 | 25.25 Mn |
| Mar 31, 2024 | 22.82 Mn |
| Dec 31, 2023 | 18.86 Mn |
| Sep 30, 2023 | 19.17 Mn |
| Jun 30, 2023 | 18.54 Mn |
| Mar 31, 2023 | 15.09 Mn |
| Dec 31, 2022 | 17.49 Mn |
| Sep 30, 2022 | 15.78 Mn |
| Jun 30, 2022 | 16.19 Mn |
| Mar 31, 2022 | 11.99 Mn |
| Dec 31, 2021 | 10.50 Mn |
| Sep 30, 2021 | 9.55 Mn |